Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Malpighia emarginata extract is a plant-derived substance obtained from the ripe fruit of Malpighia emarginata, commonly known as acerola or Barbados cherry. The extract is exceptionally rich in vitamin C (ascorbic acid), along with other bioactive compounds such as polyphenols, carotenoids (like β-carotene), flavonoids (including naringenin and catechins), and anthocyanins. It is widely used as a dietary supplement ingredient for its antioxidant properties and immune-boosting effects[1][5][8]. In addition to its nutritional uses, Malpighia emarginata extract has demonstrated anti-inflammatory activity by lowering pro-inflammatory cytokines such as TNF-α[1]. The mechanism of action primarily involves antioxidant activity—scavenging free radicals—and modulation of inflammatory pathways. It is also incorporated into cosmetic products for skin and hair conditioning due to its protective effects against environmental stressors[3][5]. There are no specific pharmaceutical developers; it is produced by various manufacturers globally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on malpighia emarginata extract.